Dr. Clay Siegall: Leading The Fight To Develop Effective Cancer Treatments

Dr. Clay Siegall is a scientist committed to finding the best targeted cancer treatments. He’s also a savvy businessman who understands that it takes lots of money to find effective cancer treatments. Through Seattle Genetics, a cancer research facility he co-founded in 1998, he has been able to do both. At Seattle Genetics Dr. Siegall and his staff have been able to create a new generation of effective cancer treatments. To finance their work, he has raised more than $1.2 billion using public and private sources of financing.

Creating an effective balance between research and business can be a challenge. But Dr. Clay Siegall has been up to the task. Driven by a passion to improve treatment outcomes for cancer patients, his company has developed groundbreaking new drugs. He has also been able to finance his company’s work by licensing the drugs they have developed to oncologists worldwide and forming lucrative partnerships with a number of pharmaceutical companies. By working along these dual tracks, Dr. Siegall has been able to help countless cancer patients while keeping his company economically viable.

One of the most successful drugs the Dr. Siegall and Seattle Genetics’ staff have developed is ADCETRIS. This antibody-based cancer drugs received FDA approval in 2011 and has been widely used to treat a variety of types of cancer. In addition to helping cancer patients, the development of this drug has helped to triple the value of Seattle Genetics stock. It has also helped to make them an industry leader. Dr. Siegall has also raised funds for the company by leading them through a very successful IPO in 2001.

The success Dr. Clay Siegall has had with the business side of running Seattle Genetics led Ernst & Young to vote him ‘Entrepreneur of the Year’ in 2012. In addition to the gratitude of countless cancer patients worldwide Dr. Siegall has received for his groundbreaking scientific discoveries, his alma mater, the University of Maryland, voted him ‘Alumnus of the Year’ in 2013. These are but a few of the awards and accolades Dr. Clay Siegall has been given for his amazing work.

Dr. Clay Siegall Extends his Efforts in the Field of Cancer Research

Clay Siegall Ph.D. is a powerful force in the field of cancer research. He co-founded Seattle Genetics in 1998 where he serves as the company’s CEO, president and the chairman of the board of directors. Seattle Genetics is a company dedicated to finding cures for cancers and in helping to ease the suffering of cancer patients. They have developed a group of antibody-based therapies that specifically attack cancer cells while leaving healthy cells unharmed. Their drug, ADCETRIS which was recently given accelerated approval by the U.S. Food and Drug Administration in 2011 shows incredible promise.
Siegall was appointed to the board of directors of Mirna Therapeutics, an Austin, Texas-based company founded in 2007 that like Siegall’s Seattle Genetics is focused on cancer research. Mirna Therapeutics has made advances in the realm of microRNA, an area of keen interest for Siegall. The combining of these two powerful companies researching and developing cures for cancer shows the altruistic goals of both Mirna Therapeutics and Siegall.
Siegall began his interest in oncology as a student at the University of Maryland studying Zoology. Siegall continued his education at George Washington University where he received his Ph.D. in Genetics. Before co-founding Seattle Genetics, he worked for the National Cancer Institute, the National Institute of Health, and the Bristol-Myers Squibb Pharmaceutical Research company. He has written extensively in his field of expertise, publishing 70 works along with obtaining 15 patents in his field of endeavor.
Mirna Therapeutics is fortunate to have Dr. Siegall on its board of directors, and the world is lucky to have a scientist and researcher like Dr. Siegall searching for cures to a terrible disease.